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Background: With the increase in production and use of engineered nanoparticles (NP; ≤ 100 nm), safety concerns
have risen about the potential health effects of occupational or environmental NP exposure. Results of animal
toxicology studies suggest that inhalation of NP may cause pulmonary injury with subsequent acute or chronic
inflammation. People with chronic respiratory diseases like asthma or allergic rhinitis may be even more susceptible
to toxic effects of inhaled NP. Few studies, however, have investigated adverse effects of inhaled NP that may
enhance the development of allergic airway disease.
Methods: We investigated the potential of polyethylene glycol coated amorphous silica NP (SNP; 90 nm diameter)
to promote allergic airway disease when co-exposed during sensitization with an allergen. BALB/c mice were
sensitized by intranasal instillation with 0.02% ovalbumin (OVA; allergen) or saline (control), and co-exposed to 0, 10,
100, or 400 μg of SNP. OVA-sensitized mice were then challenged intranasally with 0.5% OVA 14 and 15 days after
sensitization, and all animals were sacrificed a day after the last OVA challenge. Blood and bronchoalveolar lavage
fluid (BALF) were collected, and pulmonary tissue was processed for histopathology and biochemical and molecular
analyses.
Results: Co-exposure to SNP during OVA sensitization caused a dose-dependent enhancement of allergic airway
disease upon challenge with OVA alone. This adjuvant-like effect was manifested by significantly greater OVA-specific
serum IgE, airway eosinophil infiltration, mucous cell metaplasia, and Th2 and Th17 cytokine gene and protein
expression, as compared to mice that were sensitized to OVA without SNP. In saline controls, SNP exposure did cause a
moderate increase in airway neutrophils at the highest doses.
Conclusions: These results suggest that airway exposure to engineered SNP could enhance allergen sensitization and
foster greater manifestation of allergic airway disease upon secondary allergen exposures. Whereas SNP caused innate
immune responses at high doses in non-allergic mice, the adjuvant effects of SNP were found at lower doses in
allergic mice and were Th2/Th17 related. In conclusion, these findings in mice suggest that individuals exposed to SNP
might be more prone to manifest allergic airway disease, due to adjuvant-like properties of SNP.
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Engineered nanoparticles (NP) have unique and desir-
able functional properties, due to their extremely small
size (≤ 100 nm). As a result, NP have an enormous eco-
nomic potential and are rapidly being introduced into
commercial products, such as textiles, cosmetics and food
packaging [1]. Recent reviews [2,3], however, have
presented compelling evidence that occupational exposure
during the production of NP might have significant health
risks. Due to their small size and potential for airborne dis-
persion, inhalation of NP may be a plausible route of hu-
man exposure in the workplace. Under certain conditions,
inhalation of NP could potentially exacerbate or contribute
to the onset of common respiratory diseases, such as
chronic bronchitis, asthma or allergic rhinitis [3,4].
Asthma and other allergic airway diseases are a world-
wide health problem. In the United States approximately
26 million people suffer from asthma (National Health
Interview Survey, National Center for Health Statistics,
CDC, 1980–2009). Asthma is characterized by reversible
airway obstruction, airway hyperresponsiveness (AHR),
increased production of immunoglobulin isotype IgE,
airway inflammatory cell infiltrates of eosinophils and
CD4+ T helper type 2 (Th2) lymphocytes, mucus
hypersecretion, and airway remodeling (e.g., epithelial
mucous cell metaplasia, intramural interstitial fibrosis).
Various factors have been recognized to exacerbate
asthma such as indoor and outdoor allergens, tobacco
smoke and air pollution [5]. In urban air pollution, par-
ticulate matter (PM) is a well-recognized risk factor, caus-
ing exacerbation of asthmatic symptoms (e.g., dyspnea,
airway constriction, airway mucus hypersecretion). In
addition, results of recent animal toxicology studies have
demonstrated that exposure to intranasally aspirated
ultrafine PM (UFP; < 100 nm) during sensitization with
ovalbumin (OVA), a commonly used experimental aller-
gen, can enhance the development and severity of allergic
airway disease in mice [6,7]. UFP acted as adjuvants to
boost the secondary immune response upon subsequent
OVA challenge. In these studies, the adjuvant potential of
UFP was closely associated with their oxidant potential
[7]. These laboratory findings 1) suggest a plausibleTable 1 Grafting amount and size of SNP after different steps
(aSNP), to alkyne-modified (aaSNP) and to final PEG-coated S
Sample Weight Loss (%)a Grafting amount (t,
plain SNP 1.7g 1.9h
aSNP 3.6 0.63
aaSNP 2.4 0.29
PEG-coated SNP 3.6 0.15
aWeight loss, grafting amount and density were calculated for each modification st
as mono-distribution after sonication for 30-60 min. c Size was measured in H2O.
d
was measured in DMF. g Weight loss of water from surface of bare silica particle. h
calculated from water loss.biological mechanism for epidemiological reports that PM
exposure caused enhancement of morbidity in humans
with allergic airway disease [8] and 2) provide a reprodu-
cible in vivo murine model to test the potentially adverse
adjuvant effects of other NP, such as engineered NP that
have distinctive physical and chemical characteristics.
In the present study, we used an OVA-induced murine
model of asthma to test the hypothesis that engineered
amorphous silica nanoparticles (SNP) may act as inhaled
adjuvants to enhance allergic airway disease. SNP are
used as additives to cosmetics, drugs, printer toners, var-
nishes and food [9]. It is well known that chronic inhal-
ation exposure of coarse-sized (2.5 to 10 μm), crystalline
silica particles can lead to a debilitating fibrotic condi-
tion known as pulmonary silicosis [10]. In contrast, syn-
thetic amorphous silica particles are thought to be much
less toxic to the lung. Inhalation of engineered amorph-
ous silica causes only minimal and transient pulmonary
inflammation in laboratory rodents [11,12] and no fibro-
sis of the lungs [13,14] as compared to crystalline silica
particles. Few toxicology studies have been conducted to
examine the adverse effects of inhaled amorphous SNP
and, to the best of our knowledge, no studies have been
designed to investigate the potential of these NP to act
as adjuvants to enhance the development or exacerba-
tion of allergic airway disease.
The adjuvant potential of SNP was determined by
assessing the magnitude of OVA-induced histopatho-
logical and immunological responses in the lung of mice,
which were intranasally instilled with 0, 10, 100 or
400 μg SNP, at four distinct times, along with OVA (i.e.,
antigen sensitization with or without SNP) and 14 days
prior to subsequent OVA challenge. Amorphous SNP
had a hydrodynamic diameter of 90 nm (Table 1) and
were coated with a polyethylene glycol (PEG) shell to
prevent them from agglomeration [15]. A scheme of the
study design is presented in Figure 1.
Results
OVA induced allergic airway disease
Animals that were treated with OVA without SNP
(OVA-mice) had a significant (p ≤ 0.05) 2-fold increaseof synthesis: plain SNP (SNP) to amine-modified SNP
NP





ep, not for total modification. b Size were measured by dynamic light scattering
Size was measured in dimethylformamide triethylamine (DMF-TEA) (3:1). e Size
Grafting amount and density of Si-OH available for modification on the surface
Figure 1 Study design and exposure scheme. Mice were sensitized intranasally (IN) on days 1, 3, 6 and 8 with 0.02% OVA or saline (SAL). SNP
were co-administered at intranasal doses of 0, 10, 100, or 400 μg with OVA or saline. On days 22 and 23, OVA-mice were challenged intranasally
with 0.5% OVA and SAL-mice with saline solution. Animals were sacrificed on day 24, 24 hours after the last intranasal challenge.
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mice (SAL-mice; 68,750 ± 14,372 and 135,833 ± 21,337
for SAL- and OVA-mice, respectively). This increase
in total cells was due to a significant increase in neu-
trophils, eosinophils and lymphocytes (Figure 2).
Whereas no eosinophils or neutrophils were detected
in the BALF of SAL-mice, 2.2% and 39% of BALF cells
were eosinophils and neutrophils in the OVA-mice
(Figure 2B and C). In addition, lymphocytes were 7-foldFigure 2 Differential BALF cell counts. Differential counts of macrophag
assessed in all study groups. •: Significant changes (p < 0.05) when compare
to SAL-mice.greater in OVA-mice, compared to SAL-mice, and
accounted for 11% of the BALF cells in these animals
(Figure 2D).
OVA sensitization and challenge also caused expres-
sion of OVA-specific IgG1 antibodies in serum, another
characteristic feature of a type II hypersensitivity im-
mune response to this foreign antigen (Figure 3A). How-
ever, no elevation of OVA-specific serum IgE antibodies
was detected in OVA-mice (Figure 3B).es (A), neutrophils (B), eosinophils (C) and lymphocytes (D) were
d to non-SNP exposed animals, *: significant changes when compared
Figure 3 OVA specific IgE and IgG1 expression. Serum levels of
OVA specific IgG1 (A) are detected by an ELISA and presented as
total serum concentration. OVA-specific IgE levels (B) are measured
as optical density (OD). •: Significant changes (p < 0.05) when
compared to non-SNP exposed animals, *: significant changes when
compared to non-allergic controls.
Figure 4 Pulmonary histopathology. A diagram illustrates the
locations of transverse tissue sections taken from the left lung lobe
for microscopic examination (A). Light photomicrographs of
representative lung sections taken at the level of the fifth axial
airway (AA) generation and stained with hematoxylin and eosin
(B-F). Representative light photomicrographs of a control animal
(SAL-mouse; B), OVA-mouse (C) and SNP/OVA-mice with
increasing SNP exposure doses (D-F) illustrating peribronchiolar
and perivascular mixed inflammatory cell infiltration in OVA- and
SNP/OVA-mice (arrows). Greater airway-associated inflammation is
present in SNP/OVA-mice exposed to concentrations of 100 and
400 μg SNP (E and F, respectively) compared to the SAL- and
OVA-mice. Scale bars = 1 mm.
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and perivascular mixed inflammatory cell influx, that was
principally located in the proximal aspect of the lung lobe
(G5 tissue section; Figure 4A-C). This airway inflamma-
tory response to OVA was most prominent around large
diameter pre-terminal bronchioles with occasional ex-
tension to the more distal terminal bronchioles. OVA
treatment also caused airway epithelial remodeling charac-
terized by mucous cell metaplasia, as identified with Alcian
Blue (pH 2.5)/Periodic Acid–Schiff (AB/PAS) staining for
intraepithelial neutral and acidic mucosubstances in pul-
monary bronchiolar epithelium (Figure 5). Normally the
bronchiolar epithelium of mice has no or very few such
secretory cells. This metaplastic epithelial response was re-
stricted primarily to large-diameter pre-terminal bronchi-
oles in the proximal G5 lung section of OVA-treated mice
(Figure 5A). Morphometrically, the volume density of
AB/PAS-stained mucosubstances in the proximal (G5)
axial airway of the left lung lobe did not reveal any signifi-
cant difference between SAL- and OVA-mice (Figure 5E).
However, lungs of OVA-mice also had an induced gene
expression of mucin 5 AC (Muc5ac) and chloride channelcalcium activated 3 (Clca3, Gob5), both of which are asso-
ciated with goblet cell hyperplasia as well as airway mucus
secretion in allergic airway disease [16]. There was a sig-
nificant 4.6-fold increase in Muc5ac gene expression in
OVA-mice relative to SAL-mice (Figure 5F).
Adjuvant effects of SNP
The exposure of SNP during OVA sensitization (SNP/
OVA-mice) resulted in an exacerbation of allergic airway
disease after OVA challenge, hence implying an adjuvant
effect of SNP in the development of asthma. The adju-
vant effect observed in SNP/OVA-mice increased with
SNP dose (0, 10, 100, 400 μg SNP/animal).
Total BALF cells were significantly increased up to
2.5-fold in SNP/OVA-mice compared to OVA-mice
(135,833 ± 21,337, 257,917 ± 48,958, 323,333 ± 40,284 and
345,833 ± 66,476 for OVA- and SNP/OVA-mice with SNP
doses of 10, 100 and 400 μg, respectively). The adjuvant
effect was consistently demonstrated in the number of
BALF eosinophils. Significant, dose-dependent increases
Figure 5 Airway epithelial mucus production. Increase in airway
epithelial mucus, as a feature of allergic airway disease, was analyzed
on lung tissue at the 5th generation of the intraepithelial AB/PAS
stained mucosubstances (arrows) in SNP/OVA-mice with increasing
SNP exposure dose are shown in figure A (0 μg), B (10 μg), C
(100 μg) and D (400 μg); AA = axial airway, e = airway epithelium, a
= alveoli, bv = blood vessel. Morphometric measurement of
intraepithelial AB/PAS mucosubstances are further shown in E and
changes in Muc5ac and Clca3 gene expression in F. •: Significant
changes (p < 0.05) when compared to non-SNP exposed animals, *:
significant changes when compared to non-allergic controls.
Figure 6 Immunohistochemistry of airway-associated
eosinophils. Light photomicrographs of peri-bronchiolar and –
vascular interstitium surrounding the proximal axial airway (AA) at
generation 5. Tissues were immunohistochemically stained for
eosinophils (murine-specific anti-major basic protein antibody; red
chromagen; arrows) and counterstained with hematoxylin. OVA-
induced inflammatory cell infiltrate composed of eosinophils and
mononuclear cells (lymphocytes and plasma cells) is dose-
dependently enhanced by SNP. Figures A-D are taken from OVA-
treated mice that were co-exposed to 0 (saline control), 10, 100 and
400 μg SNP, respectively. bv: blood vessel; e: airway epithelium; a:
alveolus; Scale bars = 50 μm.
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compared to OVA-mice (11-, 14- and 25-fold increases
for 10, 100 and 400 μg SNP/OVA co-exposures respect-
ively; Figure 2C). A significant increase was also observed
for BALF lymphocytes in SNP/OVA-mice relative to
OVA-mice (2.9-, 5.0- and 4.4-fold for 10, 100 and 400 μg
SNP/OVA, respectively; Figure 2D). No adjuvant-related
increases were found for macrophages and neutrophils
(Figure 2A and B).
Serum OVA-specific IgG1 antibody levels (Figure 3A)
were significantly elevated (1.6-fold) in 100 and 400 μg
SNP/OVA-mice compared to OVA-mice. A significant
increase in OVA-specific IgE antibodies levels was also
detected in 400 μg SNP/OVA-mice (Figure 3B), which
was not present in any other exposure group. A systemic
allergic response was observed only in mice exposed to
SNP during OVA sensitization at the highest SNP dose.
Microscopically there was a SNP dose dependent,
peribronchiolar and perivascular mixed inflammatory cell
influx in SNP/OVA-mice, that was principally located in
the proximal lung lobe (G5 tissue section), with someextension into the distal lung lobe (Figure 4C-F). The in-
flammatory cell influx was composed mainly of lympho-
cytes and lesser numbers of eosinophils (Figure 6). This
airway inflammatory response to OVA and SNP/OVA was
most prominent around large diameter pre-terminal bron-
chioles with extension to the more distal terminal bron-
chioles. Inflammatory cell infiltration was also evident in
the interstitial tissues surrounding pulmonary arteries ad-
jacent bronchiolar airways and pulmonary veins embed-
ded in the alveolar parenchyma.
Intracellular mucosubstances in epithelial cells lining
the proximal axial airway (G5) increased with increasing
SNP dose in the SNP/OVA-mice (Figure 5A-E). There
was a significant 6 to 7-fold increase in 100 and 400 μg
SNP/OVA-mice compared to OVA-mice. Gene expres-
sion analysis of Muc5ac and Clca3 revealed 5.5-fold
(p < 0.001) overexpression of Muc5ac in 400 μg SNP/
OVA as compared to OVA-mice (Figure 5F).
SNP co-sensitization induces a Th2/Th17 cytokine
response in OVA-mice
To investigate the mechanisms of SNP adjuvancy in
the development of allergic airway disease, a gene ex-
pression array of lung tissue and BALF cytokine ex-
pression analysis were performed. For gene expression
analysis, 96 genes were chosen as part of different gene
clusters (i.e. chemokines, cytokines and other immune
responsive genes, mucus/surfactant production and
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and redox response as well as transcription factors). A
detailed list of all genes is available in the supplemental
information (Additional file 1: Table S1) as well as an
expression heat map of all analyzed genes (Additional
file 1: Figure S5). For BALF cytokine analysis, a panel
of acute phase, Th1, Th2 and Th17 cytokines and
chemokines was used, including interleukin-1β (IL1β),
IL2, IL4, IL5, IL6, IL 13 and IL17, keratinocyte chemo-
attractant (KC; CXCL1), macrophage inflammatory
protein 1α (MIP-1α; CXCL3), monocyte chemoattract-
ant protein 1 (MCP-1; CCL2), tumor necrosis factor α
(TNFα), and interferon γ (IFNγ).
Gene expression analysis was first performed with
pooled cDNA of all individuals within a study group
(n = 6 animals/group). Relevant changes in gene ex-
pression levels (>2 fold of SAL-mice; calculated with
relative ΔΔCt method) in OVA- and SNP/OVA-mice
were found in gene clusters of chemokines, cytokines
and inflammation as well as of mucus/surfactant pro-
duction and secretion. These results are presented as a
heat map in Figure 7. No elevated changes were found
in other gene clusters, such as those for cell cycle and
growth factors, oxidative stress or transcription factors
(Additional file 1: Figure S5). To confirm findings ob-
served in the aforementioned gene arrays, a full qPCR
analysis on non-pooled, individual samples of SAL-
mice, OVA-mice, 400 μg SNP-mice and 400 μg SNP/
OVA-mice was performed on genes with >2 fold
change compared to control.
The results and evaluation of the selected genes are
presented in Table 2. SNP/OVA-mice showed a signifi-
cant elevation in gene expression of Th2 cytokines (Il4,
Il5, Il13) and Th17 cytokines and related genes (Il17a;
Il6; serum amyloid A3, Saa3) compared to OVA-mice.
Gene expression of monocyte and eosinophil chemokines
such as Mcp-1 (Ccl2), Mcp-2 (Ccl8), inflammatory protein
(Ip10, Cxcl10) and eotaxin (Ccl11) were further signifi-
cantly increased in OVA- and SNP/OVA-mice, as well as
genes of proteins that are associated with tissue re-
modeling such as tissue inhibitor of metalloproteinase
1 (Timp1) and resistin-like molecule alpha (Retnla,
Fizz1). TIMP1 antagonizes tissue remodeling induced
by metalloproteinase 9 [17] and FIZZ1 is an early bio-
marker for tissue remodeling in asthma [18]. Though
all these genes were significantly elevated in both
OVA- and SNP/OVA-mice compared to SAL-mice, the
response was always greater in SNP/OVA-mice. This
was also the case for regulatory T cell (T-reg) cytokines
and transcription factor (Il10; forkhead protein P3,
Foxp3). The adjuvant Th2/Th17 cytokine response was
also confirmed in BALF analysis (Figure 8). Acute phase
cytokines (TNFα, IL1β), Th2 cytokines (IL4, IL5, IL13)
and Th17 cytokines (IL17A, IL6) were significantlyincreased in SNP/OVA-mice at SNP doses of 400 μg and
IL4, IL5 and IL17A already in SNP/OVA-mice exposed at
100 μg SNP. OVA exposure, without SNP, did not induce
an increase in BALF cytokines, with the only exception of
KC, a neutrophil activation chemokine, which was ele-
vated in both OVA- and SNP/OVA-mice. Furthermore a
significant increase in Th1 cytokine IFNγ was observed, as
evidenced by increased gene expression in lung tissue of
OVA- and SNP/OVA-mice and increased cytokine levels
in BALF of SNP/OVA-mice. However, there was no adju-
vant increase for the Th1 cytokine IL2.
Effects of SNP in SAL-mice
In animals that were exposed to SNP only (SNP-mice), there
was a significant dose-dependent increase in neutrophils at
100 and 400 μg SNP with 3,210 ± 1,583 and 5,400 ± 1,999
neutrophils/mL BALF respectively, compared to non at 0 μg
SNP (Figure 2B). No increases in BALF eosinophils and
lymphocytes were detected (Figure 2C and D) and SNP ex-
posure was not associated mucus airway remodeling
(Figure 5E and F).
SNP exposure by itself, without OVA, resulted in sig-
nificant gene expression of neutrophil chemokines Kc
and Mip-2, as well as Tnfα, immunoresponsive gene 1
(Irg1) and intelectin1 (Itln1) (Table 2). In addition, there
were significant increases of BALF chemokines KC and
MIP-1α in SNP-mice (100 and 400 μg SNP) as compared
to SAL-mice (Figure 8). These findings corresponded to
the increase in BALF neutrophils in 100 and 400 μg SNP-
mice (Figure 2B).
Enhanced activation of tracheobronchial lymph node cells
from SNP/OVA -mice
To further investigate the effect of engineered SNP on
lymphocytes and myeloid cells, activation of immune
cell populations was assessed using tracheobronchial
lymph node (TBLN) preparations. CD69 is constitu-
tively expressed by platelets, mature thymocytes and
monocytes, while it is induced on cells of hematopoietic
lineages, including T and B lymphocytes, NK cells, murine
macrophages, neutrophils, and eosinophils [19,20]. There-
fore, CD69 was used as a marker to assess the activation
status of cells in TBLN. The data within a group was
concatenated and presented as a histogram (Figure 9). Sta-
tistically significant changes between OVA- and SNP/
OVA-mice were tested with an unpaired t-test, comparing
the percent CD69 expressing cells from individual ani-
mals. Apparent increases of CD69 expression on CD4+ T
cells (Figure 9A) and Gr-1+ cells (Figure 9B) from SNP/
OVA-mice (10 μg SNP) compared to OVA-mice, were not
statistically significant. However, a significant (p > 0.05)
increase for CD69 expression was observed on CD11c+
cells (Figure 9C). CD11c is expressed primarily on den-
dritic cells (DC) and macrophages, at lower levels on
Figure 7 Heat map of gene expression array. Gene expression in
lung tissue was analyzed with a 96-gene array. Relative increased gene
expression towards control is indicated in red (≥2 fold expression) and
relative decreased gene expression in green (≤2 fold). Black labels
indicate no differences in gene expression. Increased gene expression
in allergic and SNP exposed animals was found for various cytokines,
chemokines and immune responsive genes as well as secretory
mucus/surfactant genes. No changes greater than 2-fold were found
for oxidative stress response, growth factors and different transcription
factors (Additional file 1: Figure S5).
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Gr-1 is a granulocyte marker, but is also expressed at
moderate levels on plasmacytoid dendritic cells (pDC)
in lymphoid tissues [22]. CD11c+ and Gr-1+ cell popula-
tions were further dissected to identify the cellular compo-
nents that contributed to the increased expression of CD69
in SNP/OVA-mice. Interestingly, CD11c+Gr-1+CD11b-
pDC showed enhanced surface CD69 expression in the
presence of SNP compared with the OVA alone group
(Figure 9D). In addition, alveolar macrophages (AM)
with the typical phenotype CD11c+Gr-1-CD11b-
exhibited the same CD69 expression profile (Figure 9E)
[23]. The percent of CD69+ cells in both pDC and AM
populations were statistically increased in the SNP/
OVA-mice as compared with the OVA-mice (p < 0.05).
Activation of lymphocytes was also studied by
assessing maturation status of antigen presenting cells
(APC), which was determined by expression levels of
surface MHC II molecules [24]. In SNP/OVA-mice,
CD11c+ cells also displayed a higher level of MHC II
expression compared with the CD11c+ cells from
OVA-mice (Figure 9F), though not statistically signifi-
cant. In summary, immune cells from TBLN in SNP/
OVA-mice exhibited a more elevated activation status
compared with cells from OVA-mice.
Discussion
The results of the present study indicate that airway ex-
posure to engineered SNP during sensitization of mice
to OVA enhances pathologic aspects of allergic airway
disease upon secondary OVA challenge. This effect was
more profound with increasing SNP doses and was char-
acterized by enhancement of OVA-induced eosinophilic
and lymphocytic inflammation, Th2 and Th17 cytokine
expression, elevation of serum OVA-specific IgE and
IgG1 levels, as well as an enhanced manifestation of mu-
cous cell metaplasia in pulmonary airways. The fact that
SNP exposure during allergen sensitization enhanced
the pulmonary allergic response to the secondary OVA
challenge indicates that SNP exhibits adjuvant-like char-
acteristics in the development of allergic airway disease.
Adjuvants are defined as compounds that are not im-
munogenic themselves, but increase and/or modulate
the intrinsic immunogenicity of an antigen. Adjuvants
Table 2 Detailed gene expression analysis of responsive genes
Gene
symbol
Gene alias Gene function Saline/0 μg NP Saline/400 μg NP OVA/0 μg NP OVA/400 μg NP
Cxcl1 KC Neutrophil chemokine 1.00+/−0.05 2.80+/−0.78a 2.48+/−0.28b 6.29+/−0.38a,b
Cxcl2 MIP-2 PMN chemokine 1.00+/−0.08 2.85+/−0.75a 4.22+/−0.76b 8.77+/−0.99a,b
Cxcl10 IP10 T-cell chemokine 1.00+/−0.05 1.17+/−0.05 14.32+/−3.95b 44.84+/−4.29a,b
Ccl2 MCP-1 Monocyte and T-cell chemokine 1.00+/−0.08 1.50+/−0.28 3.66+/−0.86b 13.84+/−1.71a,b
Ccl8 MCP-2 Monocyte chemokine 1.00+/−0.08 1.56+/−0.25 15.48+/−5.22b 105.12+/−32.47a,b
Ccl11 Eotaxin Eosinophil chemokine 1.00+/−0.05 1.32+/−0.11 2.50+/−0.71 11.47+/−2.84a,b
Itln1 Itlna Pathogen-associated molecular pattern recognition 1.00+/−0.25 4.95+/−1.78a 6.14+/−0.95b 38.65+/−13.92a,b
Irg1 Irg1 Toll like receptor response 1.00+/−0.14 4.70+/−1.15a 15.45+/−4.36b 154.18+/−16.97a,b
Chi3l3 YM1 Chitinase-like protein 1.00+/−0.07 1.01+/−0.12 1.30+/−0.26 1.94+/−0.28b
Chi3l4 YM2 Chitinase-like protein 1.00+/−0.35 4.61+/−2.98 9.13+/−3.96 33.10+/−12.56b
Saa3 Saa3 Acute phase protein 1.00+/−0.09 4.51+/−1.85 65.9+/−12.7b 157.88+/−19.38a,b
Tnfα TNFα Acute phase response cytokine 1.00+/−0.12 1.69+/−0.17a 2.20+/−0.23b 3.36+/−0.30b
Il6 IL6 Acute phase response cytokine 1.00+/−0.13 −1.14+/−0.13 2.00+/−0.40b 5.60+/−0.96a,b
Il1β IL1β Acute phase response cytokine 1.00+/−0.13 1.01+/−0.05 1.26+/−0.03 1.71+/−0.13b
Il1rn IL1rn IL1 receptor antagonist 1.00+/−0.04 1.13+/−0.07 1.70+/−0.23 4.62+/−0.71a,b
Il2 IL2 Th1 cytokine 1.00+/−0.06 1.06+/−0.07 1.57+/−0.24b 1.37+/−0.09
Ifnγ IFNγ Th1 cytokine 1.00+/−0.08 −1.06+/−0.14 1.67+/−0.28b 2.31+/−0.30b
Il4 IL4 Th2 cytokine 1.00+/−0.15 1.01+/−0.12 1.40+/−0.26 3.77+/−0.77a,b
Il5 IL5 Th2 cytokine 1.00+/−0.10 −1.20+/−0.18 2.39+/−0.59 7.17+/−1.44a,b
Il13 IL13 Th2 cytokine 1.00+/−0.10 1.34+/−0.39 6.80+/−2.96b 44.23+/−12.67a,b
Retnla Fizz 1, HIMF Th2 suppressor 1.00+/−0.12 1.32+/−0.37 6.88+/−1.78b 21.90+/−3.98a,b
Il17a IL17A Th17 cytokine 1.00+/−0.16 2.52+/−0.69 8.34+/−2.32b 46.24+/−6.02a,b
Foxp3 Foxp3 T-reg transcription factor 1.00+/−0.08 1.49+/−0.18 2.08+/−0.19b 3.98+/−0.33a,b
Il10 IL10 T-reg cytokine 1.00+/−0.09 1.09+/−0.17 2.97+/−0.76b 8.22+/−2.01a,b
Muc5ac Muc5ac Mucin production 1.00+/−0.19 1.61+/−0.61 4.72+/−1.44b 25.97+/−4.70a,b
Clca3 Gob5 Ion channel, mucus secretion 1.00+/−0.39 2.52+/−1.42 6.16+/−2.26 16.72+/−3.42b
Clca2 Clca2 Ion channel, fibrosis development 1.00+/−0.12 1.40+/−0.16 3.25+/−0.78b 7.96+/−1.20a,b
Mmp12 Mmp12 Macrophage elastase 1.00+/−0.08 3.06+/−0.81 1.83+/−0.22 7.91+/−0.59
Timp1 Timp1 Mmp inhibitor 1.00+/−0.05 −1.00+/−0.10 3.73+/−0.87b 12.40+/−1.68a,b
A qPCR analysis was performed on the genes that showed a ≥2 fold increase towards untreated controls in the gene array. a: Significant changes (p < 0.05)
towards non-SNP exposed animals, b: significant changes towards non-OVA mice. The analysis reveals that neutrophil chemokines (Kc, Cxcl1; Mip-2, Cxcl2) and
innate immune responsive genes (Tnfα; Irg1; Itln1) are significantly elevated by SNP exposure in both, SAL- and OVA-mice. A significant adjuvant SNP effect in
SNP/OVA-mice was measured for Th2 cytokines (Il4; Il5; Il3) and Th17 associated genes (Il17a; Il6; Saa3). Monocyte and eosinophil chemokines (Mcp-1; Mcp-2;
Eotaxin; Ip10) were further significantly increased in SNP/OVA-mice as well as other proteins which might be involved in tissue remodeling (Fizz1; Timp1). No
adjuvant SNP effect was measured in Th1 cytokines (Ifnγ; Il2).
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mune responses, with the additional benefits that less
antigen and/or fewer injections are needed [25]. In this
study, however, SNP promoted the immunologic re-
sponse towards the allergen (OVA) and thereby potenti-
ated the adverse allergic responses in the pulmonary
airways.
Our results suggest that workplace exposures to
engineered NP could have similar adverse health conse-
quences as those reported for UFP in outdoor air pollu-
tion associated with high traffic roadways. UFP collected
from the Los Angeles Air Basin have been shown to actas adjuvants to enhance the development and severity of
allergic airway disease, using a similar OVA-induced
murine model of asthma [6]. In addition, epidemiologic
studies have reported an increased incidence of asthma
in children living in close proximity to highway traffic
[26,27], where ambient UFP concentrations are high
[28]. By comparison, relatively few studies have investi-
gated the exacerbation of allergic airway disease by other
types of NP exposures. Exacerbation in allergic airway
disease, with increased Th2 responses, have been
reported in OVA-sensitized and -challenged mice when
co-exposed with 50 μg multi-walled carbon nanotubes
Figure 8 Expression of BALF cytokines and chemokines. Different BALF cytokine expression profiles were analyzed by an ELISA as for KC,
MIP-1α, MCP-1, TNFα, IFNγ and IL1β, IL2, IL4, IL5, IL6, IL13, IL17A. •: Significant changes (p < 0.05) when compared to non- SNP exposed animals, *:
significant changes when compared to non-allergic controls.
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Similar findings were reported by Hussain et al. in mice
sensitized with toluene diisocyanate (TDI) via skin and ex-
posed to TiO2 NP and gold NP via instillation (0.8 mg/kg
body weight) [31]. Unlike our study design, mice in these
studies were co-exposed to NPs during both the
sensitization and challenge phases of the allergen adminis-
tration. In our study we found that inhaled SNP during
sensitization phase alone can act as adjuvants to markedly
increase the magnitude of the host’s secondary immune
response upon subsequent allergen challenge. A similar
effect was also found previously for nano-sized crystalline
silica particles [32]. However, a recent study by Ban and
colleagues [33] addressed the same question in a similar
OVA mouse model with iron oxide NP, and found that
iron NP exposure during sensitization with OVA results
in attenuation of OVA mediated allergic airway disease.
This suggests that the adjuvant effect of SNP in the devel-
opment of allergic airway disease, we observed in our
study, is likely to be particle specific. Further research,
however, is needed to understand the immune modulatory
effects of different NP and the impact of NP material, size
and surface coating.In our study, SNP exposure alone, without the antigen,
caused a dose-dependent pro-inflammatory response in
non-allergic animals as indicated by a modest increase
in BALF neutrophils and elevations of neutrophil-related
chemokines and innate immune response genes, namely
Kc, Mip-1α, Mip-2, Itln1 and Irg1. These effects were
evident at SNP exposure doses of 100 and 400 μg and
demonstrate that these engineered SNP at high dose
cause a minimal, yet sustained, innate immune responses
up to 16 days post-instillation. By comparison, many ro-
dent SNP toxicity studies describe airway neutrophilic
inflammation that is accompanied by overt toxicity and
tissue injury. For example, persistent pulmonary toxicity
[13,34], including neutrophilic inflammation, apoptosis,
tissue injury [13,35], the induction of pro-inflammatory
BALF cytokines such as IL1β, IL6 and TNFα [34] as well
as cardiovascular effects [36] have been reported. These
studies used smaller sized SNP (14 nm) at similar or
higher exposure doses (100 μg/mouse [13]; 3 mg/mouse
[35]). Compared to these in vivo studies, we used larger
SNP (90 nm), which appear to be less toxic than smaller
SNP reported by others [9]. The SNP used in ours study
were further modified with a PEG shell which prevents
Figure 9 Activation of immune cells from TBLN. Cells from TBLN
of OVA- and SNP/OVA-mice (10 μg SNP) were stained for expression
of surface molecules, including CD4, CD69, CD11c, CD11b, MHC II,
and Gr-1. Cells were gated on singlets using FSC-A/FSC-H,
lymphocytes, monocytes, or granulocytes using FSC-A/SSC-A, and
individual cell populations, including CD4+ cells, CD11c+, Gr-1+,
CD11c+Gr-1+CD11b- pDC, CD11c+Gr-1-CD11b- AM. More details on
the gating strategy are found in the supplementary information
(Additional file 1: Figure S6). Expression of CD69 on CD4+ cells (A),
Gr-1+ cells (B), CD11c+ cells (C), pDC (D), and AM (E), and expression
of MHC II on CD11c+ cells (F) are presented in histograms, with X
axis representing mean fluorescence intensity for CD69 or MHC II
and Y for % of particular gated cell population. Six samples from
OVA- (grey curve) or OVA/SNP- (black curve) mice were
concatenated for flow cytometric analysis. Statistical analysis of
percent values of CD69 expression from individual TBLN revealed a
significant difference in CD11c+, AM, and pDC populations between
OVA and SNP/OVA-mice.
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penetrate rapidly through airway mucus barriers [37].
PEG-coatings have been reported to decrease systemic
NP interactions and overall toxicity [38-40], which might
explain the less severe acute inflammatory response we
observed compared to those reported by others.
Adjuvant effects described in the current study had a
mixed Th2/Th17 cytokine response, similar to findings
by Li et al. who used ambient UFP in a similar OVA
model [6]. Mechanisms by which SNP may induce an
adjuvant Th2/Th17 cytokine response can only be spec-
ulated, since this study was not designed to investigatethe underlying mechanisms of adjuvancy in detail. SNP
are known to induce oxidative stress [9], which plays
an important role in the pathogenesis of asthma [7,41].
This connection has been shown by Li et al. for ambi-
ent UFP where co-administration with the anti-oxidant
N-acetylcysteine in OVA challenged mice diminished
the adjuvant allergic airway response of UFP [7]. In an-
other study, oxidative stress, caused by diesel enriched
PM, was also shown to skew the immune response
from a Th1 to a Th2 cytokine profile [42]. It has been
suggested that oxidative stress-induced activation of
transcription factor NF-E2-related factor 2 (NRF2),
during the sensitization phase with an allergen, can
down regulate the production of Th1 cytokines IL12
and IFNγ [43] and thereby leads to a Th1/Th2 imbal-
ance. Furthermore results from in vitro studies on
amorphous, colloidal SNP in a size range of 14 to
80 nm show a size- and dose-dependent cytotoxicity of
SNP with induction of oxidative stress and/or glutathi-
one (GSH) depletion [44,45]. At the time point after
challenge, however, we did not detect any signs of oxi-
dative stress. Further investigations are therefore
needed to assess oxidative stress and Th1/Th2 cyto-
kine balance during the sensitization phase of our
protocol in order to address these potential mecha-
nisms of SNP-associated adjuvancy.
Recently IL17 has been associated with more severe
forms of asthma, especially those cases complicated by
persistent airway neutrophils [46]. Th17 responses in al-
lergic airway disease are promoted by IL6, tumor growth
factor β (TGFβ), IL23, SAA3 as well as IL1β [47,48]. In
our study we detected significant increases in allergic
SNP/OVA-mice of IL17A, IL6 and IL1β (cytokine and
gene expression) as well as Saa3 (gene expression). SAA3
has been shown to activate the NLRP3 inflammasome and
promote an allergic Th17 response in mice in com-
bination with other mediators [47]. The NLRP3
inflammasome is a protein complex required for spli-
cing pro-IL1β into its active form [49], and was re-
cently found to have an immuno-stimulatory function
for aluminum adjuvants in vaccination [50]. Though
we did not measure inflammasome activation in the
present study, SNP treatment caused a dose- dependent
increase in BALF IL1β, and a recent study has shown that
SNP can activate the inflammasome [51]. It is therefore
possible that the SNP-mediated adjuvant effects in allergic
models are related to inflammasome activation and/or
oxidative stress. However, further studies are needed to
elucidate their roles in the adjuvant effects of SNP in more
detail.
Besides Th2 and Th17 cytokine responses, we also
detected an increase in TNFα and Th1 cytokine IFNγ in
the SNP/OVA-mice which was not detectable in SNP-
or OVA-mice. Therefore it may be possible that a Th1
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SNP/OVA-mice. It has been shown previously, that Th1
cells do not attenuate Th2 cell–induced airway
hyperreactivity in OVA-immunized BALB/c mice, but
rather cause severe airway inflammation [52]. We there-
fore suggest that the increase in BALF cytokines TNFα
and IFNγ are augmenting rather than attenuating the al-
lergic response in our model.
Besides stimulation of Th2 response, NP have also
been shown to influence maturation, antigen presenta-
tion and co-stimulation of DC [53], and the analysis of
TBLN cell populations in our study confirmed these
findings. In response to DNA and RNA viruses, pDC se-
crete large amounts of IFN-α and IFN-β that play im-
portant roles in activating other cells in the immune
system. For example, IFN-α and IFN-β produced by
pDC have been shown to increase CD69 expression and
IFN-γ production from CD4+ T cells [54,55], and also
activate CD8+ T cells upon influenza challenge [56]. Up-
regulation of CD69 on pDC in response to influenza in-
fection has been found to cause down-regulation of
sphingosine-1-phosphate (S1P) on pDC, resulting in
elongated transit time of pDC and their accumulation in
LN [57]. An OVA-induced CD69 up-regulation on pDC
might therefore lead to retention of pDC in TBLN
where they could interact with lymphocytes and stimu-
late an immune response. The CD69 expression on pDC
was further increased by co-exposure with SNP. Although
AM have been suggested to prevent development of air-
way hyperresponsiveness upon OVA challenge [58], AM
are also known to produce proinflammatory cytokines
that enhance Th2 cytokine production by pulmonary
CD4+ T lymphocytes [59]. In our study, the activation
of AM was further increased in the presence of SNP
and an increase in BALF Th2 cytokines was measured.
In addition, OVA-induced maturation of CD11c+ cells,
including APC, such as DC and macrophages, was also
exaggerated by SNP. Koike et al. further confirmed
that effects on APC parallel those on allergic pathology
in vivo in their overall trend [60]. These mechanisms
might partly explain the SNP-mediated immune en-
hancement; however, further research is still required
to understand interaction of NPs with the immune sys-
tem, which could include additional surface markers to
further refine effects of NPs on various myeloid
subpopulations.
In our treatment protocol, mice were IN instilled with
a wide range of SNP doses (0, 10, 100 or 400 μg SNP
per instillation). The applied doses of SNP used in our
study are comparable to those used in similar studies
performing intratracheal (IT) or IN administration
[13,29,30,32,33]. IN has been shown to be an easily ap-
plicable and efficient method to administer particle sus-
pensions in murine models [61]. Nevertheless, particleinhalation represents a more realistic model for NP
workplace exposure. Intrapulmonary NP delivery and
distribution might differ between inhalation and instilla-
tion exposure which may result in different dose re-
sponses. The potential workplace exposure levels for
SNP, however, are currently not known and it is there-
fore difficult to estimate a realistic dosing regimen. It
has been reported that airborne, crystalline silica parti-
cles may reach as high as 0.28 mg/m3 in some workplace
conditions such as cement mason/concrete finisher [62].
In summary, the results of our study indicate that
engineered SNP can act as adjuvants to enhance the de-
velopment of allergic airway disease in mice. This find-
ing further suggests that individuals exposed to SNP
might be more prone to develop allergic airway diseases,
establishing a new aspect of NP toxicity that has particu-
lar relevance to occupational NP exposure. More re-
search, however, is needed to clarify the potential risks
of NP exposure in the development of allergic airway
diseases in humans. Nevertheless, the murine allergic
OVA model we used in our study, which involved IN in-
stillation of allergen and SNPs during sensitization
followed by IN challenge with allergen only, may be used
to test the adjuvant potential of other NPs in allergic air-
way disease.
Material and methods
Particle preparation and characterization
Plain SNP (LUDOX® TM-40 colloidal silica, 40 wt% sus-
pension in H2O), aminopropyltriethoxysilane (APTES),
propargyl chloroformate and sodium azide were purchased
from Sigma-Aldrich. Anhydrous dimethylformamide
(DMF) was freshly distilled from powered BaO. Cu
(PPh3)Br and 1-azido-2-(2-(2-(2-methoxyethoxy)eth
oxy)ethoxyethane (PEG-N3) were prepared as previ-
ously described in detail [63,64]. PEG-modified SNP
were synthesized from commercially available LTM40
SNP in three steps (shown in Additional file 1: Figure S1).
To avoid aggregation, the modified SNP were purified by
several steps of washing the NP with solvent, followed by
centrifugation. Resulting particles were used directly
to the following step and aggressive drying such as
drying under vacuum was avoided [65]. First, APTES
was condensed on plain SNP. The resulting amine-
modified SNP (aSNP) were washed twice with reagent
grade DMF, and then three times with anhydrous
DMF to remove ethanol and water. aSNP were
reacted with propargyl chloroformate to afford the
alkyne-modified particles (aaSNP) which were purified
by centrifugation. The resulted particles were clicked
with PEG-N3 catalyzed by 10% of Cu(PPh3)Br in
DMF. The resulted SNP were purified by centrifuga-
tion to receive the PEG-coated SNP. Note that the
SNP suspension was not tested for endotoxin content.
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sensitization with OVA might suppress the development
of a Th2 cytokine response [66], which was not the
case in our study.
Dynamic Light Scattering (DLS) was performed with a
Malvern NanoZS ZetaSizer to measure the particle
hydrodynamic size and intensity average diameters. The
particle samples for DLS analyses were sonicated prior
to DLS measuring. Particle size, surface grafting amount
at different step of synthesis are shown in Table 1. The
final SNP used for the animal exposure study had a
hydrodynamic diameter of 90 nm. Zeta potential of the
particles was not measured, however, the size distribu-
tion measurements of the particles (Additional file 1:
Figure S4) only shows a single peak at 90 nm and there-
fore suggesting single SNP dispersion. A more detailed de-
scription of particle synthesis and characterization can be
found in the supplementary information (Additional file 1).
Experimental protocol
Female BALB/c mice (~20 grams body weight; 6–8 weeks
old) were obtained from Charles River (Portage, MI).
Mice were maintained at the Michigan State University
(MSU) animal housing facilities at room temperature of
21°C–24°C and relative humidity of 45–70%, with a 12 h
light/dark cycle starting at 7:30 A.M. All animal proce-
dures and experimental protocols were approved by the
MSU Institutional Animal Care and Use Committee;
MSU is an AAALAC accredited institution.
On days 1, 3, 6 and 8, BALB/c mice were intranasally
sensitized with 0.02% OVA (allergen; Sigma-Aldrich) in
saline or saline alone (vehicle control) at a volume of
15 μL per nostril (total intranasal volume of 30 μL)
(n = 6 animals/group). SNP were co-administered with in-
tranasal doses of 0, 10, 100, or 400 μg (Figure 1). On days
22 and 23, OVA-sensitized mice were challenged intrana-
sally with 30 μL of a 0.5% OVA in saline solution. All mice
were anesthetized with 4% isoflurane prior to each intra-
nasal aspiration. Animals were sacrificed 24 hours after
the last intranasal challenge (Day 24).
Necropsy, lavage collection and tissue preparation
Mice were anesthetized with an intraperitoneal injection
of sodium pentobarbital (60 mg/kg body weight). A mid-
line laparotomy was performed and approximately
0.5 mL of blood was drawn from the vena cava and col-
lected in heparinized tubes (BD Microtainer, Franklin
Lakes, NJ) for separation of plasma. Animals were
exsanguinated via the abdominal aorta. Immediately
after death, the trachea was exposed and cannulated and
the heart and lungs were excised en bloc. A volume of
0.8 mL sterile saline was instilled through the tracheal
cannula and withdrawn to recover bronchoalveolar lav-
age fluid (BALF). A second intratracheal saline lavagewas performed and the collected BALF was combined
with the first sample for analysis.
After the BALF was collected, the right lung lobes were
ligated, removed and placed in RNAlater (Qiagen, CA).
Samples were kept at − 20°C until further processing for
RNA isolation. The left lung lobe was intratracheally fixed
with neutral-buffered formalin at a constant pressure
(30 cm H2O) for 2 h and then stored in a large volume of
the same fixative until further tissue processing for light
microscopy.
Twenty-four hours later, two sections were excised at
the level of the 5th and 11th airway generation along the
main axial airway (G5 and G11), to sample proximal and
distal bronchiolar airways, respectively [67]. Tissue blocks
were then embedded in paraffin and 5- to 6-μm-thick
sections were cut from the anterior surface. Lung
sections were stained with hematoxylin and eosin
(H&E) for routine light microscopic examination and
with Alcian Blue (pH 2.5)/Periodic Acid–Schiff (AB/PAS)
for identification of intraepithelial neutral and acidic
mucosubstances in pulmonary bronchiolar epithelium.
To detect eosinophils, slides were immunostained using a
polyclonal rabbit antibody directed against murine
eosinophil-specific major basic protein (MBP; 1:500; Mayo
Clinic, AZ).
In OVA- and OVA/SNP-mice (10 μg SNP), TBLN
were removed en bloc from the mice, and homogenized
in 1× PBS. Single-cell suspensions were prepared, and
1 × 106 cells from each sample were collected in a 96
well round-bottom plate for flow cytometric analysis.
BALF cytometry
Total number of cells in the collected BALF was esti-
mated using a hemocytometer. All intact cells were
counted, but no trypan blue exclusion test of dead cells
was performed. Cytological slides were prepared by cen-
trifugation at 400 g for 10 min using a Shandon cytospin
3 (Shandon Scientific, PA) and stained with Diff-Quick
(Dade Behring, DE). Differential cell counts for neutro-
phils, eosinophils, macrophages/monocytes, and lym-
phocytes were assessed from a total of 200 cells.
Remaining BALF was centrifuged at 2400 g for 15 min
and the supernatant fraction was collected and stored
at −80°C for later biochemical analysis.
Flow cytometric analyses for inflammatory cytokines
BALF supernatants were assayed for the inflammatory
cytokines IL-1β, IL-2, IL4, IL-5, IL-6, IL-13, IL-17A,
TNFα, IFN-γ, MCP-1, MIP-1α and KC. All cytokine kits
were purchased as either Flex Set reagents or as
preconfigured cytometric bead array kits (BD Biosci-
ences, San Jose, CA). Cytokine analysis was performed
using a FACSCalibur flow cytometer (BD Biosciences).
50 μL of BALF was added to the antibody-coated bead
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secondary antibodies were added to form sandwich com-
plexes. After acquisition of sample data using the flow
cytometer, cytokine concentrations were calculated based
on standard curve data using FCAP Array software (BD
Biosciences).
Flow cytometric analyses for surface markers
Cells from TBLN were incubated with purified rat
anti-mouse CD16/CD32 (Fc block; BD Pharmingen,
San Diego, CA) in FACS buffer (1× HBSS, 1% bovine
serum albumin (BSA), 0.1% sodium azide, pH 7.6).
Cells were then stained for surface markers using fol-
lowing antibodies from Biolegend (San Diego, CA):
phycoerythrin (PE)/cy7-conjugated anti-mouse CD4
(clone RM4-5), Pacific Blue-conjugated anti-mouse
CD11b (clone M1/70), allophyeocyanin (APC)/cy7-
conjugated anti-mouse CD11c (clone N418), fluores-
cein isothiocyanate (FITC)-conjugated anti-mouse MHC
II (I-A/I-E, clone M5/114.15.2), APC-conjugated anti
mouse Gr-1 (granulocyte differentiation antigen 1, clone
RB6-8C5), and PE-conjugated anti-mouse CD69 (clone
H1.2 F3). Cells were fixed with Cytofix (BD Pharmingen)
and analyzed using a FACSCanto II flow cytometer (BD
Biosciences, San Jose, CA). A graph, explaining the ap-
plied gating strategy, is presented in the supplementary in-
formation (Additional file 1: Figure S6). Samples were
concatenated (n = 6) and further analyzed using Kaluza
1.1 software (Beckman Coulter, Miami, FL). The fluores-
cence intensity values for CD69 or MHC II expression by
different populations were presented in histograms. To
determine the statistically significant changes between
OVA and SNP/OVA groups, an unpaired t-test was
performed on non-concatenated data. The percent values
of CD69 expression by CD4+, CD11c+, Gr-1+, AM, and
pDC populations, respectively, or the percent values of
MHC II expression by CD11c+ population from individual
animal were transformed and analyzed using GraphPad
Prism v4.0 (Graphpad Software, San Diego, CA).
ELISA assay OVA- IgE/IgG1
OVA-specific IgE and IgG1 expression in serum was an-
alyzed with an ELISA kit (BD PharMingen, CA) as de-
scribed previously [6]. 96 well plates (Costar, NY) were
coated overnight with 50 μg/mL OVA. After washing
with phosphate buffered saline (PBS) and blocking with
10% fetal bovine serum (FBS)/PBS, samples and stan-
dards were loaded and incubated overnight. Following
additional washing steps, detection antibody (biotin-con-
jugated rat anti-mouse IgG1 or IgE Antibody (BD
PharMingen, CA) was applied and incubated for 4 h. Fi-
nally, streptavidin-horseradish peroxidase mixture was
added for 30 min, followed by 20 min incubation with
reaction substrate. Optical density (OD) was read at405 nm wave length with a Spectra Max Gemini plate
reader (Molecular Devices, CA). The OVA-IgG1 stand-
ard was a monoclonal anti-chicken egg albumin (Sigma-
Aldrich, MO). Since no standard was available for IgE,
OVA-specific IgE was determined only by OD. All sam-
ples were loaded and measured on the same 96-well
plate, therefore a standard was not essential for compar-
ing relative increases in IgE concentrations.
Real-time PCR of pulmonary tissues
Total RNA was isolated from right lung lobes using RNeasy
Mini Kit (Qiagen, CA) according to the manufacturer’s
instructions. Briefly, tissues were homogenized in lysis
buffer (Buffer RLT) containing 2-mercaptoethanol with a
5 mm rotor-stator homogenizer (PRO Scientific, CT).
During RNA purification, DNase digestion was performed
on-column using Qiagen RNase-Free DNase Set. Purified
RNA was quantified using a GeneQuant Pro spectropho-
tometer (BioCrom, England). CDNA was generated from
2 μg of total RNA using the High-Capacity cDNA Reverse
Transcription Kit. The reaction mixture was incubated at
25°C for 10 min and then 37°C for 2 h. PCR array analysis
was performed by pooling aliquots of cDNAs from samples
in each experimental group. Quantitative gene expression
analysis was performed using TaqMan Gene Expression
Assay reagents on the ABI PRISM 7900 HT Sequence
Detection System. The PCR cycling parameters were
48°C for 2 min, 95°C for 10 min, and 50 cycles of 95°C
for 15 s followed by 60°C for 1 min. Relative gene expres-
sion levels were reported as fold-change using the ΔΔCt
method where FC = 2−ΔΔCt. The mRNA expression of
each gene was normalized by subtracting the geometric
mean of the Cts from four endogenous controls (Actb,
Arbp, Gapd, Gusb). Selected genes that had expression
levels at least 2-fold greater in experimental groups
relative to the control group were confirmed by rela-
tive quantitative real-time RT-PCR using individual
animal cDNAs as described above. Statistical differ-
ences between ΔCt values of different groups were
determined with two-way ANOVA (SigmaStat, Ashburn,
VA; P ≤ 0.05).
Airway morphometry
Morphometric estimation of the amount of intraepithelial
AB/PAS mucosubstances was conducted as previously de-
scribed [68]. These quantitative analyses were performed
using Scion Image (Scion Corporation, MD), to estimate
the volume density (VDmuc) of AB/PAS stained
mucosubstances stored in mucus-secreting cells of the
bronchiolar epithelium lining the axial airways G5 and
G11 and using the equation below. The area of
mucosubstance (Amuc) in the respiratory epithelium
lining the cross-sections of selected axial airways was
sampled within a random field of interest and
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(LBL) (Equation 1.)
VDmuc ¼ AmucLBL  4=∏ ð1Þ
Statistics
Each study group consisted of 6 mice and all data were
reported as group means ± standard error of the mean
(SEM). Grubbs outlier test was performed and recog-
nized outliers were removed from the analysis. Differ-
ences among groups were analyzed by a two-way
ANOVA followed by a pair-wise comparison (Student-
Newman-Keuls). When normality or variance equality
failed, a Kruskal-Wallis ANOVA on ranks was performed.
All analyses were conducted using SigmaStat software
(SigmaStat; Jandel Scientific, San Rafael, CA). Significance
was assigned to p values less than or equal to 0.05.
Additional file
Additional file 1: Additional information on material and methods.
Further information on the design of engineered silica nanoparticles and
on the gene expression analysis of the lung tissue are provided in the
Additional file 1, as well as more detailed information on the gating
strategy for FACS.
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reg: Regulatory T cells; UFP: Ultrafine particles; VDmuc: Volume density of
mucus.
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